Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) Equity Average (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Equity Average data on record, last reported at $9.1 million in Q3 2025.

  • For Q3 2025, Equity Average rose 6.64% year-over-year to $9.1 million; the TTM value through Sep 2025 reached $9.1 million, up 6.64%, while the annual FY2024 figure was $10.1 million, 7.37% down from the prior year.
  • Equity Average reached $9.1 million in Q3 2025 per CYCN's latest filing, up from $8.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $60.8 million in Q3 2021 and bottomed at $4.5 million in Q2 2023.
  • Average Equity Average over 5 years is $22.6 million, with a median of $10.6 million recorded in 2024.
  • Peak YoY movement for Equity Average: plummeted 85.46% in 2023, then soared 106.13% in 2024.
  • A 5-year view of Equity Average shows it stood at $52.3 million in 2021, then plummeted by 74.22% to $13.5 million in 2022, then fell by 10.44% to $12.1 million in 2023, then decreased by 29.44% to $8.5 million in 2024, then increased by 6.22% to $9.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $9.1 million in Q3 2025, $8.7 million in Q2 2025, and $8.8 million in Q1 2025.